Trial reportJournal of psychopharmacology (Oxford, England)2024
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat.
Trial report in Journal of psychopharmacology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05780216 (Mindfulness and Psychedelics), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced Meditators
Who cites it
10 citing papers in PubMed.
- Enhancing mindfulness and compassion through an ayahuasca-inspired formulation containing N,N-DMT and harmine: A randomized controlled trial in healthy subjects.Journal of psychopharmacology (Oxford, England) · 2026Trial
- Mixed-methods analysis on psychedelic-augmented meditation experiences from a randomized controlled mindfulness retreat.Scientific reports · 2026Trial
- Combined DMT-harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers.Psychopharmacology · 2026Article
- Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review.Clinical pharmacology and therapeutics · 2026Article
- Towards a general-purpose foundation model for functional MRI analysis.Nature biomedical engineering · 2026Article
- Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action.Pharmacology research & perspectives · 2026Review
- The current status of foundation models in decoding inner speech from non-invasive brain signals: a mini review.Frontiers in human neuroscience · 2026Review
- Can psychedelic use benefit meditation practice? Examining individual, psychedelic, and meditation-related factors.PloS one · 2025Article
- Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study ofImaging neuroscience (Cambridge, Mass.) · 2025Article
- Music mindfulness acutely modulates autonomic activity and improves psychological state in anxiety and depression.Frontiers in neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, both meditation and psychedelics have attracted rapidly increasing scientific interest. While the current state of evidence suggests the promising potential of psychedelics, such as psilocybin, to enhance meditative training, it remains equivocal whether these effects are specifically bound to psilocybin or if other classical psychedelics might show synergistic effects with meditation practice. One particularly promising candidate is
aimThis study aims to investigate the effect of the psychedelic substance DMT, combined with the monoamine oxidase inhibitor harmine (
methodForty experienced meditators (18 females and 22 males) participated in a double-blind, placebo-controlled study over a 3-day meditation retreat, receiving either placebo or DMT-harmine. Participants' levels of mindfulness, compassion, insight, and transcendence were assessed before, during, and after the meditation group retreat, using psychometric questionnaires.
resultsCompared to meditation with a placebo, meditators who received DMT and harmine self-attributed greater levels of mystical-type experiences, non-dual awareness, and emotional breakthrough during the acute substance effects and, when corrected for baseline differences, greater psychological insight 1 day later. Mindfulness and compassion were not significantly different in the DMT-harmine group compared to placebo. At 1-month follow-up, the meditators who received DMT and harmine rated their experience as significantly more personally meaningful, spiritually significant, and well-being-enhancing than the meditators who received placebo.
conclusionInvestigating the impact of DMT-harmine on meditators in a naturalistic mindfulness group retreat, this placebo-controlled study highlights the specific effects of psychedelics during meditation.
trial registrationClinicalTrials.gov identifier NCT05780216.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.